Lenvima (lenvatinib) vs Afinitor (everolimus)

Lenvima (lenvatinib) is a multikinase inhibitor used primarily for the treatment of certain types of thyroid cancer, renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC), and it works by blocking the growth of cancer cells by inhibiting multiple molecular targets. Afinitor (everolimus), on the other hand, is an mTOR inhibitor that is also used to treat advanced RCC, as well as progressive neuroendocrine tumors of pancreatic origin, advanced hormone receptor-positive, HER2-negative breast cancer, and subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis, functioning by interrupting the growth of cancer cells and reducing blood supply to the tumor. When deciding between the two, it is crucial to consider the specific type of cancer, the patient's overall health, potential side effects, and the mechanism of action of each drug, as they have different indications and modes of operation; a healthcare provider would make a recommendation based on the individual's unique medical profile and the cancer's characteristics.

Difference between Lenvima and Afinitor

Metric	Lenvima (lenvatinib)	Afinitor (everolimus)
Generic name	Lenvatinib	Everolimus
Indications	Thyroid cancer, Renal cell carcinoma, Hepatocellular carcinoma	Renal cell carcinoma, Pancreatic neuroendocrine tumors, Breast cancer, Subependymal giant cell astrocytoma, Tuberous sclerosis complex
Mechanism of action	Tyrosine kinase inhibitor	mTOR inhibitor
Brand names	Lenvima	Afinitor, Zortress
Administrative route	Oral	Oral
Side effects	Hypertension, Diarrhea, Fatigue, Decreased appetite, Weight loss, Joint and muscle pain	Stomatitis, Infections, Rash, Fatigue, Diarrhea, Decreased appetite
Contraindications	Hypersensitivity to lenvatinib or excipients	Hypersensitivity to everolimus or other rapamycin derivatives
Drug class	Multikinase inhibitor	Immunosuppressant, mTOR inhibitor
Manufacturer	Eisai Co., Ltd.	Novartis Pharmaceuticals

Efficacy

Efficacy of Lenvima (Lenvatinib) in Kidney Cancer

Lenvima (lenvatinib) is a medication that has shown efficacy in the treatment of advanced renal cell carcinoma (RCC), which is the most common type of kidney cancer. Lenvatinib is a tyrosine kinase inhibitor that targets multiple pathways involved in tumor growth and angiogenesis. The efficacy of lenvatinib for kidney cancer was demonstrated in a clinical trial known as the SELECT trial, which showed that lenvatinib, in combination with everolimus, significantly improved progression-free survival compared to everolimus alone in patients with advanced RCC who had previously received anti-angiogenic therapy.

Efficacy of Afinitor (Everolimus) in Kidney Cancer

Afinitor (everolimus) is an mTOR inhibitor used in the treatment of advanced renal cell carcinoma after failure of initial therapy with sunitinib or sorafenib. Everolimus works by inhibiting the mammalian target of rapamycin (mTOR), a protein that plays a critical role in the proliferation and growth of cancer cells. The RECORD-1 study was pivotal in demonstrating the efficacy of everolimus in patients with metastatic RCC, showing a significant extension in progression-free survival when compared to placebo in patients who had progressed on previous VEGF-targeted therapies.

Combination Therapy in Kidney Cancer

The combination of Lenvima (lenvatinib) and Afinitor (everolimus) has been studied as a treatment option for patients with advanced renal cell carcinoma. The aforementioned SELECT trial provided evidence that this combination therapy significantly improved outcomes for patients with advanced RCC. The trial results showed not only an improvement in progression-free survival but also suggested an improvement in overall response rate when lenvatinib and everolimus were used together, compared to everolimus alone or lenvatinib alone.

Conclusion

Both Lenvima (lenvatinib) and Afinitor (everolimus) have demonstrated efficacy in the treatment of advanced renal cell carcinoma, both as monotherapies and in combination. The use of these drugs represents an important advancement in the management of kidney cancer, particularly for patients who have progressed on prior therapies. The combination of lenvatinib and everolimus has become a valuable treatment option, offering hope for improved outcomes in the battle against this challenging disease. It is important for patients to discuss with their healthcare providers the potential benefits and risks of these therapies to determine the most appropriate treatment strategy for their individual condition.

Regulatory Agency Approvals

Lenvima

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia

Afinitor

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia

Access Lenvima or Afinitor today

If Lenvima or Afinitor are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Lenvima

Buy Afinitor

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: